[1]翟宇瑶,段万里,胡斌,等.活血化瘀类中药注射剂临床应用合理性分析[J].西部中医药,2021,34(05):112-115.[doi:10.12174/j.issn.2096-9600.2021.05.28]
　ZHAI Yuyao,DUAN Wanli,HU Bin,et al.An Analysis of Clinical Application Rationality of TCM Injection for Blood-activating Stasis-removing[J].Western Journal of Traditional Chinese Medicine,2021,34(05):112-115.[doi:10.12174/j.issn.2096-9600.2021.05.28]
点击复制

活血化瘀类中药注射剂临床应用合理性分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年05期
页码:
112-115
栏目:
调查分析
出版日期:
2021-05-15

文章信息/Info

Title:
An Analysis of Clinical Application Rationality of TCM Injection for Blood-activating Stasis-removing
作者:
翟宇瑶1, 段万里2, 胡斌1, 薛小荣1, 王静1, 闵慧1
1.西安交通大学医学院附属广仁医院/西安市第四医院药剂科，陕西 西安 710004
2.陕西省人民医院泌尿外科
Author(s):
ZHAI Yuyao1, DUAN Wanli2, HU Bin1, XUE Xiaorong1, WANG Jing1, MIN Hui1
1.Guangren Hospital Affiliated to Xi′an Jiaotong University Health Science Center / Pharmacy Department, Xi′an No.4 Hospital, Xi′an 710004, China
2.Department of Urinary Surgery, Shaanxi Provincial People′s Hospital
关键词:
活血化瘀; 中药注射剂; 合理性分析; 联合用药
Keywords:
blood-activating stasis-removing; TCM injections; rationality analysis; drug combination
分类号:
R944.1
DOI:
10.12174/j.issn.2096-9600.2021.05.28
摘要:
目的分析某医院活血化瘀类中药注射剂的应用状况，为临床合理用药提供参考。 方法抽取某医院2018年1～12月期间使用活血化瘀类中药注射剂住院患者病历，对活血化瘀类中药注射剂的临床应用进行分析。 结果765份病历中活血化瘀类中药注射剂不合理现象包括：联用未冲管占59.87%（458/765）、适应症不合理占21.44%（164/765）、配伍禁忌占10.72%（82/765）、超疗程用药占7.45%（57/765）、重复用药占5.62%（43/765）、溶媒选择错误占3.14%（24/765）。 结论该院活血化瘀类中药注射剂临床应用有待进一步提高，应在中医药理论指导下使用，以确保临床合理用药。
Abstract:
ObjectiveTo provide the reference for clinical rational use by analyzing the application status of TCM injections for blood-activating stasis-removing in a hospital. MethodsClinical application of TCM injections for blood-activating stasis-removing was analyzed after selecting the medical records of the inpatients who were given TCM injections for blood-activating stasis-removing from January to December of 2018 in a hospital. ResultsUnreasonable phenomenon of 765 cases of using TCM injections for blood-activating stasis-removing contained:no flushing pipe in drug combination 59.87%(458/765), unreasonable indication 21.44%(164/765),incompatibility 10.72%(82/765), the medication beyond the course 7.45%(57/765), repeat medication 5.62%(43/765), wrong selection of solvent 3.14%(24/765). ConclusionClinical application of TCM injections for blood-activating stasis-removing in the hospital needs to be further improved, it should be used under the guidance of TCM theory to ensure rational clinical application.

相似文献/References:

[1]刘滢.中药注射剂不良反应中的不合理用药分析[J].西部中医药,2014,27(07):57.
　LIU Ying.Analysis of Improper Drug Use Existed in Adverse Reactions of TCM Injection[J].Western Journal of Traditional Chinese Medicine,2014,27(05):57.
[2]乔丽娟.中药注射剂静脉输液安全管理[J].西部中医药,2015,28(07):75.
[3]李红,马军党,王莉,等.中药注射剂说明书与合理用药相关性分析[J].西部中医药,2013,26(10):75.
　LI Hong,MA Jundang,WANG Li,et al.Analysis on the Relation between Rational Use and TCM Injection Instructions[J].Western Journal of Traditional Chinese Medicine,2013,26(05):75.
[4]张彩莲,付世龙△.中药注射剂不良反应分析及护理对策[J].西部中医药,2012,25(12):103.
　ZHANG Cai-lian,FU Shi-long.Analysis of Adverse Drug Reactions Induced by TCM Injections and Its Nursing Method[J].Western Journal of Traditional Chinese Medicine,2012,25(05):103.
[5]杨有文.活血化瘀治疗脑挫裂伤的临床研究[J].西部中医药,2013,26(10):92.
　YANG Youwen.Clincal Study on Treatment for Contusion and Lacteration of Brain with the Method of Activating Blood and Removing Stasis[J].Western Journal of Traditional Chinese Medicine,2013,26(05):92.
[6]李艳梅,宋立中,万红棉,等.针药并用治疗高血压病肝热血瘀证疗效观察[J].西部中医药,2018,31(09):117.
　LI Yanmei,SONG Lizhong,WAN Hongmian,et al.Clinical Observation on Treating Hypertension of Liver-heat and Blood Stasis Pattern by Combination of Acupuncture and Medicines[J].Western Journal of Traditional Chinese Medicine,2018,31(05):117.
[7]张小荣,杨涛.李妍怡教授活血化瘀学术思想探讨[J].西部中医药,2016,29(02):47.
　ZHANG Xiaorong,YANG Tao.Preliminary Exploration on Professor Li Yanyi′s Academic Thinking of Promoting Blood Circulation and Eliminating Blood Stasis[J].Western Journal of Traditional Chinese Medicine,2016,29(05):47.
[8]于子凯,付长庚,吴永健,等.冠状动脉微血管疾病的中西医结合研究进展[J].西部中医药,2019,32(05):135.
　YU Zikai,FU Changgeng,WU Yongjian,et al.Research Progress of Combined Therapy of Chinese and Western Medicine for Coronary Microvascular Disease[J].Western Journal of Traditional Chinese Medicine,2019,32(05):135.
[9]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(05):149.
[10]蔡莉.某三级甲等中医院PIVAS中药注射剂不合理医嘱分析[J].西部中医药,2020,33(01):102.[doi:10.12174/j.issn.1004-6852.2020.01.27]
　CAI Li.An Analysis of Unreasonable Medical Advice of TCM Injection in PIVAS of a Tertiary First - class TCM Hospital[J].Western Journal of Traditional Chinese Medicine,2020,33(05):102.[doi:10.12174/j.issn.1004-6852.2020.01.27]

备注/Memo

备注/Memo:
翟宇瑶（1988—），女，硕士学位，主管药师。研究方向：药物质量控制。陕西省重点研发计划项目（S2018-YF-YBSF-0167）；西安市中医药局科研项目（SZL201909）；西安市第四医院院内孵化课题（FZ-39）。
更新日期/Last Update: 2021-05-15